Ganetespib (STA-9090)

For research use only.

Catalog No.S1159

37 publications

Ganetespib (STA-9090) Chemical Structure

CAS No. 888216-25-9

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 302 In stock
USD 270 In stock
USD 370 In stock
USD 1070 In stock
USD 2470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Ganetespib (STA-9090) has been cited by 37 publications

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1975 NFvpclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;1O|IhcA>? MmnnTWM2OD16IH7N NHTocmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG0OFY3PSd-MkKxOFQ3PjV:L3G+
NCI-H1975 M33zcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\qZlc1QCCq MnPuTWM2OD1zNjDuUS=> MlvvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNES2OlUoRjJ{MUS0OlY2RC:jPh?=
Calu-6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfVVXZKSzVyPU[0JI5O MoG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
Calu-1 NGTXOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\wRmlEPTB;NUigcm0> M33selxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H2122 M4DseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInEcYpKSzVyPUWzJI5O NXXhRXZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
A549 Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTR|IH7N MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
H358 M3vj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJ7IH7N MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
H1734 NX3DNlNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ6IH7N MnnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H727 M1yzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJ6IH7N MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
COR-L23 NYXCcld1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\PPFhKSzVyPUKyJI5O M1qz[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H1792 NIfqSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX5[Y1KSzVyPUKwJI5O NVjtXXpHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
H2009 NFPhfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjpTWM2OD1zOTDuUS=> NYPOfGpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
SK-LU-1 NHLqPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvlVWcxUUN3ME2xPEBvVQ>? NVK4T4J1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
H2212 M1jRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\4UWlEPTB;MUegcm0> MkjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H441 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHXTWM2OD1zNDDuUS=> MoDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H2030 NEjUUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF{IH7N M3zBcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H23 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFzIH7N MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
HOP-62 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFzIH7N MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
IA-LM Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXCXlNIUUN3ME2xNEBvVQ>? NFXUfYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H460 M1KyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7LTWM2OD16IH7N NXzEVXNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
H157 NGX0Z2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfyZWQ{UUN3ME23JI5O M{XDWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H1355 NFK3bIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTVibl2= M3TlN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
VCaP M1nxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr2TWM2OD15IH7N Mn:2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNUKwNFQoRjJ|MUWyNFA1RC:jPh?=
LNCaP NIP3VZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHneIE2UUN3ME24JI5O MoG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNUKwNFQoRjJ|MUWyNFA1RC:jPh?=
Ramos-RA1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTdwNDDuUS=> NGnNelc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
Karpas-299 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTtTWM2OD17Lk[gcm0> M{O0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CzO|QyLz5{M{OwN|c1OTxxYU6=
Kasumi-1 M2LJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjyTWM2OD13Lkigcm0> MnPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
CCRF-CEM (2) M33x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Psd2lEPTB;Nz6yJI5O M13sSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CzO|QyLz5{M{OwN|c1OTxxYU6=
CCRF-CEM (1) M13ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF{LkWgcm0> NXfxXVR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
MOLT-4 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLC[pJKSzVyPUGwMlYhdk1? NEP2NY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
RS4;11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF|LkWgcm0> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
COG-LL-317 MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XVUWlEPTB;ND60JI5O MmjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
NALM-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnLXmJRUUN3ME2xNU44KG6P MkjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
CHLA-136 M1vWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH0TWM2OD1{Mz6yJI5O NGr6ZZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
CHLA-90 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ{LkOgcm0> NYGxWVZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
NB-EBc1 M1jKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGwZWNKSzVyPUG2Mlghdk1? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
NB-1643 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PyWmlEPTB;Nz60JI5O Ml2yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
SJ-GBM2 M3Tncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\GXGlEPTB;MUKuPUBvVQ>? M2jnVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CzO|QyLz5{M{OwN|c1OTxxYU6=
CHLA-258 NV7rN3Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K5emlEPTB;Nj60JI5O MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
CHLA-10 NF20VmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HORWlEPTB;NT63JI5O MonFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
CHLA-9 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVezR4xbUUN3ME20MlYhdk1? Mlj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
TC-71 NGLBcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfJTWM2OD12LkWgcm0> Mk\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
CHLA-266 NUfCUGJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG2c2JKSzVyPUK3MlEhdk1? M4PDO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CzO|QyLz5{M{OwN|c1OTxxYU6=
BT-12 MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF2LkOgcm0> NGLLUJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
Rh30 NEPr[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTVwNjDuUS=> M1PiOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CzO|QyLz5{M{OwN|c1OTxxYU6=
Rh18 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjoTWM2OD14LkKgcm0> NF\OZ4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
Rh41 NYmyWJczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LIS2lEPTB;MUCuOEBvVQ>? NIfucGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
RD M1i5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRThibl2= MmHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
K033 NYC5XphnSXCxcITvd4l{KEG|c3H5 NXzPO3pVOTByIH7N NFjWcoY4OiCq MljVd4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? M1mwe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
M23 M4X5[GFxd3C2b4Ppd{BCe3OjeR?= NVeyeYJ2OTByIH7N MnG0O|IhcA>? M4\Ed5Nq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K029 NXG0eGdCSXCxcITvd4l{KEG|c3H5 MWOxNFAhdk1? M4r1WFczKGh? NHj4W5Z{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| MlLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
K028 MUDBdI9xfG:|aYOgRZN{[Xl? Mn;SNVAxKG6P NX3JRWlbPzJiaB?= MXrzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ M3TtdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
K008 MlLqRZBweHSxc3nzJGF{e2G7 MYSxNFAhdk1? NGHxV3o4OiCq NXH3NWNWe2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= MkL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
K033 MoHQSpVv[3Srb36gRZN{[Xl? Mn\aNlUxKG6P NET4clczPCCq NYrqWXVMcW6mdXPld{BiKG2xZHXzeEBqdmO{ZXHz[UBqdiCJMTDwc5B2dGG2aX;u MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
M23 NYq0R4p3TnWwY4Tpc44hSXO|YYm= NHTC[WIzPTBibl2= Ml\nNlQhcA>? MoLybY5lfWOnczDHNUBidmRiR{KvUUBienKnc4S= NWG2UmxWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ|PD;hQi=>
K029 M2XhOmZ2dmO2aX;uJGF{e2G7 MkjkNlUxKG6P MWiyOEBp NYG1ZZducW6mdXPld{BIOSCjcoLld5Q> NGfvOok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K028 Mn:4SpVv[3Srb36gRZN{[Xl? M{D5XFI2OCCwTR?= MkfBNlQhcA>? NYOycpFZcW6mdXPld{BIOiCjcoLld5Q> NXe0NGdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ|PD;hQi=>
K008 MmTPSpVv[3Srb36gRZN{[Xl? NX3GTXFNOjVyIH7N NYC0dI5xOjRiaB?= M2HVeolv\HWlZYOgS|Ih[XK{ZYP0 NGnxUIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K033 NYPxV|JES2WubDDWbYFjcWyrdImgRZN{[Xl? MlP4TWM2OD15NT61JI5O M{j0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
M23 NHrLb5pE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUW4THRlUUN3ME2zO{42KG6P NXPC[oFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ|PD;hQi=>
K029 MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWPJR|UxRTR4IH7N M3;x[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
K028 NITCeJFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEn1XoRKSzVyPUi0JI5O MoLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
K008 M3TwS2NmdGxiVnnhZoltcXS7IFHzd4F6 NXG0fJBIUUN3ME22NEBvVQ>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
H3122 MoPFR4VtdCCYaXHibYxqfHliQYPzZZk> NGPZZ5UxNTFyMECgcm0> NV7DeYhiPzJiaB?= MXPJR|UxRTFyIH7N M{HUOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUOzNlY2Lz5{M{WzN|I3PTxxYU6=
H2228 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUewMVExODBibl2= MWq3NkBp M321XGlEPTB;MUOgcm0> MnSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{OyOlUoRjJ|NUOzNlY2RC:jPh?=
A1847 NVLHc2lMSXCxcITvd4l{KEG|c3H5 NE\HOJgyOC1zMECgcm0> MlXnNlQwPDhxN{KgbC=> MXfpcoR2[2W|IHHwc5B1d3OrczD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfGy7 Mn;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MECxN|YoRjJ|OUCwNVM3RC:jPh?=
OVCAR-8 MkW0RZBweHSxc3nzJGF{e2G7 MkXjNVAuOTByIH7N NU\GNGtWOjRxNEivO|IhcA>? MonQbY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?= NFToXpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwNFE{Pid-MkO5NFAyOzZ:L3G+
OVCAR-5 NFHPZYlCeG:ydH;zbZMhSXO|YYm= NHy1bo8yOC1zMECgcm0> NUTBTHdjOjRxNEivO|IhcA>? NFrybo1qdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5 MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyMEGzOkc,OjN7MECxN|Y9N2F-
SKOV-3 NYLF[I4xS2WubDDWbYFjcWyrdImgRZN{[Xl? MnmzNE0yODByIH7N M1rKSlczKGh? NWKwXmt3cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NXS4NINERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFAyOzZpPkKzPVAxOTN4PD;hQi=>
A1847 NUP1b|ExS2WubDDWbYFjcWyrdImgRZN{[Xl? M{fxWVAuOTByMDDuUS=> NV\0WodZPzJiaB?= MkjpbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NHvtS3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwNFE{Pid-MkO5NFAyOzZ:L3G+
OVCAR-8 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUnsWnEyOC1zMECwJI5O MX:3NkBp MXzpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 Mn:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MECxN|YoRjJ|OUCwNVM3RC:jPh?=
OVCAR-5 MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlfPNE0yODByIH7N NX;OcVdiPzJiaB?= MlLKbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M4\BR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUCwNVM3Lz5{M{mwNFE{PjxxYU6=
H146  M4HrPGZ2dmO2aX;uJGF{e2G7 MnHXN|Ahdk1? M1L3Z|czKGh? M{jTZ4lv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
GLC4 NXr4NVR7TnWwY4Tpc44hSXO|YYm= MoD5N|Ahdk1? M{LHV|czKGh? M1LaSIlv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> MkfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H82 MXHGeY5kfGmxbjDBd5NigQ>? M17BZlMxKG6P MnH3O|IhcA>? NF7WV3lqdmS3Y3XzJJBmenOrc4TlcpQhTzJxTTDwbIF{\SCjcoLld5Q> Mn;XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
AC3 M1LSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJ3Lkmgcm0> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H1173 M3Tub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzic4k1UUN3ME2xNk43OiCwTR?= Ml31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H792 NV7JV5lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTOTpFKSzVyPUS1MlA4KG6P M1;3Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
H620 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P2RmlEPTB;M{KuOlchdk1? MlnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
N592 MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3CTWM2OD1zND6xNkBvVQ>? NUD1eYRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H526 NVO5cIZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rL[WlEPTB;MkGuOlQhdk1? M3G1flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
H187 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn1foxKSzVyPUK0Mlk6KG6P NVzrVoFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H146 NE\NVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn6TWM2OD1{OD61NUBvVQ>? NY\5Z|IyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H128 Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NISzOGtKSzVyPU[5MlU2KG6P NYm2WmRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H69 NIPHendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXuTWM2OD16Mz6zOkBvVQ>? NU\qelhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
GLC4 NVfJOVg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJyLkS3JI5O M2TySVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
H82 NWixbHRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL5ZpZKSzVyPUOwMlI4KG6P NGDEcWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
MDA-MB-231 MX3GeY5kfGmxbjDBd5NigQ>? NXnLfVlTOTByIH7N NGjLcYczPCCq Mm[5bY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCjbnSgbY53[XOrdnWgZ4Fx[WOrdIpCpC=> MlrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{O1OFEoRjJ2MUezOVQyRC:jPh?=
BT-20  MnrUSpVv[3Srb36gRZN{[Xl? MY[xNFAwOjVyIH7N MX2yOEBp MUPy[ZN2dHSnZDDpckBiKGSxc3Wt[IVx\W6mZX70JIRme3SjYnnsbZpifGmxbjDv[kBGT0[ULDDJS2YuUVJuIF3FWEwh[W6mIFPSRWY> M37NR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUezOVQyLz5{NEG3N|U1OTxxYU6=
MDA-MB-435 M{\KVWZ2dmO2aX;uJGF{e2G7 MmH1NVAxKG6P MVyzNEBucW5? NIn0OoFqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gTGlHNTIQsR?= NYPVSW1SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFgzPjVpPkK0NlQ5OjZ3PD;hQi=>
MDA-MB-231 Mn3ZSpVv[3Srb36gRZN{[Xl? MlHiNVAxKG6P Mmf2N|AhdWmw MXHpcohq[mm2czDhZ4N2dXWuYYTpc44hd2ZiSFnGMVHPuQ>? Mn3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEiyOlUoRjJ2MkS4NlY2RC:jPh?=
HCC2998 M4PQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfnSYY4UUN3ME2xNlghdk1? MnrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
SK-CO-1 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjzcJNKSzVyPUixJI5O MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
LS-123 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrV[|RKSzVyPUezJI5O NFXFUXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
SNU-C2B NGTYRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXiUZdKSzVyPUS1JI5O MlHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
LS-1034 M13YW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;pUpFKSzVyPUOxJI5O NXXObWdRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
LoVo M4Pyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ{IH7N NWrE[FI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
COLO-678 NE\5WZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHpTWM2OD1{MTDuUS=> M{XKflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO|Q4Lz5{NE[4Nlc1PzxxYU6=
NCI-H747 NELGZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TKUWlEPTB;MUegcm0> NGDNeIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
COLO-205 NHPVXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPjTWM2OD1zNDDuUS=> NWHnTIszRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
HCT 116 M{LkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF2IH7N MnHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
HuTu-80 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKwTWM2OD1zMzDuUS=> MoLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
HCT-15 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ToSGlEPTB;ODDuUS=> M{PqXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO|Q4Lz5{NE[4Nlc1PzxxYU6=
SW620 MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzU[mhKSzVyPUigcm0> NUDHOWR3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
LS-411 N MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrEZYJKSzVyPUWgcm0> NUnnO5U2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
RKO NG\BVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjDTY1kUUN3ME20JI5O NUiwN2hXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
SW780 NUO0SIVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTN2NUGgcm0> NH3OV5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
RT4 NEPBPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[5[ZVNUUN3ME2xO|M{KG6P NX\NRYdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O|g1QDN7PD;hQi=>
TCCSUP NYnKXYhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHlVYFKSzVyPUG0NkBvVQ>? NEHDXYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
MGH-U3 M2PGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7IPZJjUUN3ME21N{BvVQ>? Mk\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
HT-1197 M1TFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTV|IH7N MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
5637 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfETWM2OD12NDDuUS=> MortQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
35612 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTN6IH7N M4jaPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
KU-19-19 NVrScZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTN4IH7N NIXsblI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
LB831-BLC NE\lfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nGOGlEPTB;M{Sgcm0> Mm\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
UM-UC3 MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fUfmlEPTB;M{Ogcm0> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
647-V MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X1W2lEPTB;Mkegcm0> NGfGVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
HT-1376 MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf5VY5NUUN3ME2yNUBvVQ>? M3nCVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
J82 NY[yd2R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H3ZWlEPTB;MUigcm0> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
BFTC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr6VGxIUUN3ME2xO{BvVQ>? NIDDU3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
SCaBER NUjYcoJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW3TWM2OD1zMDDuUS=> M2jQbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
639-V M3vWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[0[5VYUUN3ME2xNEBvVQ>? M4DkUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
RT112 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTlibl2= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
T24 NUnYUWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHuNmZKSzVyPUegcm0> MmPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
SW-1710 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC3e4JmUUN3ME22JI5O MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
DSH1 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjQ[Gs1UUN3ME22JI5O Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
CAL27 NHLTWnlEgXSxeHnjbZR6KEG|c3H5 MkXrNVAwPTBibl2= MW[yOEBp NVnMS|Bn\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 M3jVWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC1OFMxLz5{NUKwOVQ{ODxxYU6=
Detroit562 NVPMRnN1S3m2b4jpZ4l1gSCDc4PhfS=> NVHJOnJ6OTBxNUCgcm0> MWqyOEBp NIHFSXpl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> M1LNVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC1OFMxLz5{NUKwOVQ{ODxxYU6=
FUDA M4i0ZWN6fG:6aXPpeJkhSXO|YYm= NHfsU4MyOC93MDDuUS=> M2SwW|I1KGh? MXjk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= NH3xXpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwOVQ{OCd-MkWyNFU1OzB:L3G+
SCC25 M2PyVmN6fG:6aXPpeJkhSXO|YYm= NWDtWXpMOTBxNUCgcm0> M1i1e|I1KGh? NU[1SWox\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 NIjsbWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwOVQ{OCd-MkWyNFU1OzB:L3G+
HT-29 MnL1SpVv[3Srb36gRZN{[Xl? NGDPSlQ2OG6P MlnhNlQhcA>? MUjEUXNQ MWPpcoR2[2WmIFewM2cyKGG{cnXzeC=> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJzMEe5OEc,OjV{MUC3PVQ9N2F-
HCT-116 NVnHPYd4TnWwY4Tpc44hSXO|YYm= MYe1NI5O M1frXlI1KGh? M33RS2ROW09? MnrybY5lfWOnZDDHNE9IOSCjcoLld5Q> NHrMXWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKxNFc6PCd-MkWyNVA4QTR:L3G+
MGC-803 MXzGeY5kfGmxbjDBd5NigQ>? MkPVNE4yNTFyMECgcm0> Mki4NlQhcA>? M16wU4lv\HWlZYOgS|IwVSClZXzsMYN6[2ynIHHydoV{fA>? M3TKVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmwPFA2Lz5{NUW5NFgxPTxxYU6=
MKN-28 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1;LcVAvOS1zMECwJI5O NXLkU|U1PzJiaB?= MYrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MkW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUC4NFUoRjJ3NUmwPFA2RC:jPh?=
SGC-7901 Mkn2R4VtdCCYaXHibYxqfHliQYPzZZk> Mn\HNE4yNTFyMECgcm0> M4rM[VczKGh? NFXGOGZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MoHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUC4NFUoRjJ3NUmwPFA2RC:jPh?=
MGC-803 NWP1UYdVS2WubDDWbYFjcWyrdImgRZN{[Xl? M{DFOVAvOS1zMECwJI5O M2CxbVczKGh? MVvpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7MEiwOUc,OjV3OUC4NFU9N2F-
MV411 MV3BdI9xfG:|aYOgRZN{[Xl? MoHsN|AwQDBxMUWwM|I2OCCwTR?= MnrRNlQwPDhxN{KgbC=> NF[5WpZqdmS3Y3XzJIRwe2ViZHXw[Y5l[W62IHnu[JVkfGmxbjDv[kBieG:ydH;zbZM> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6MkW1NEc,OjV6OEK1OVA9N2F-
HL60 M4e5TGFxd3C2b4Ppd{BCe3OjeR?= M2nGT|MxNzhyL{G1NE8zPTBibl2= NWj2SlRwOjRxNEivO|IhcA>? MXPpcoR2[2W|IHTvd4Uh\GWyZX7kZY51KGmwZIXjeIlwdiCxZjDhdI9xfG:|aYO= NUXXS2pCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFI2PTBpPkK1PFgzPTVyPD;hQi=>
TC32 NYPlSYR{eUiWUzDhd5NigQ>? MnrsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN? NGXZd2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 NGO5W4xyUFSVIHHzd4F6 NVj3dlh{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= NHH2R2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 NFvFS5ByUFSVIHHzd4F6 MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NGW2WmRyUFSVIHHzd4F6 MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? NEHvZZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MWDxTHRUKGG|c3H5 Mo\QdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ NGnXcHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH M3j2cpFJXFNiYYPzZZk> M2njNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz NVzaNIJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 MkHVdWhVWyCjc4PhfS=> MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| Ml\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 MYrxTHRUKGG|c3H5 M1rjbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NFXJSGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 MmrldWhVWyCjc4PhfS=> M{XSOpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq M1X6RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 MXTxTHRUKGG|c3H5 M2rRZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz M{T1WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MXfxTHRUKGG|c3H5 Mon2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= MlKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 M{HHTZFJXFNiYYPzZZk> MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= NUn2e3hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 MlXldWhVWyCjc4PhfS=> NX3jeZhHeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz M{nXPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 M1q0PJFJXFNiYYPzZZk> NIOycWxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?= MmDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / c-Met / IGF-1Rβ/ Akt / p-Akt / ERK / p-ERK; 

PubMed: 23418523     


Downregulation of multiple signaling pathways by ganetespib in melanoma cells.A. Cells were treated with indicated amounts of ganetespib for 24 h. B-RAF and N-RAS mutational status of each cell line is indicated.

p27(Kip1) / p21 (Cip1) / Cyclin D1 / Cyclin E / Cyclin B1 / CDK1 / CDK2 / CDK4; 

PubMed: 23418523     


Alterations in expression of multiple cell cycle regulating proteins induced by ganetespib. Cells were treated with indicated amounts of ganetespib for 48 h and analyzed by Western blot analysis. Relative expression levels of proteins (treated vs. control䲧疝Ỵ疞㧀疜膉痘 

Survivin / Bcl-2 / Bcl-xl / Mcl-1; 

PubMed: 23418523     


Effect of ganetespib on the expression of antiapoptotic proteins. Cells were treated with ganetespib for 48 h and analyzed using Western blot analysis. Relative expression levels of proteins are indicated.

B-RAF / C-RAF / N-RAS ; 

PubMed: 23418523     


Effect of ganetespib on B-RAF, C-RAF and N-RAS expression in melanoma cells.Cells were treated with indicated amounts of ganetespib for 48 h and subjected to Western blot analysis.

HER2 / p-STAT3 / BIM ; 

PubMed: 25077897     


NCI-H1975 cells were incubated with the indicated concentrations of ganetespib for 24 h. Cell lysates were analyzed by Western blotting.

CDK1 / Cyclin D1 / Cyclin B1 / p27; 

PubMed: 29717218     


Cropped Western blot images of the indicated cell cycle regulators are shown in ganetespib-treated (0–300 nM for 16 hours) BT474 and SKBR3 cells. 

c-PARP / c-caspase 3 / caspase 8 / c-caspase 8 / caspase 9 / c-caspase 9; 

PubMed: 29717218     


Cropped images of Western blots at the target molecular weights for the indicated apoptotic markers are shown in ganetespib-treated (0, 10, 30, 100, 300 nM for 16 hours) BT474 and SKBR3 cells. 

ErbB2 / pErbB2 / Src / pSrc / mTOR / pmTOR / Bad / pBad / GSK3 / pGSK3; 

PubMed: 29717218     


Ganetespib inhibits RTK signaling in ErbB2+ breast cancer cells. BT474 and SKBR3 cells were treated with ganetespib (0, 10, 30, 100, or 300 nM) for 16 hours, followed by Western blot analysis (cropped images) of the expression and activation/phosphorylati䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖

Wee1 / p-Wee1 / Chk1 / p-Chk1; 

PubMed: 27834954     


Hsp90 inhibition degrades the G2/M checkpoint kinases Wee1 and Chk1. The cells were treated with 200 nM ganetespib and 75 μM carboplatin for 24 h followed by immunoblot analysis. Carboplatin treatment leads to the activation of Chk1, indicated by phospho—䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ

23418523 25077897 29717218 27834954
Growth inhibition assay
Cell viability ; 

PubMed: 23418523     


A. Ganetespib reduced viability. Cells were treated with varying amounts of ganetespib for 72 h and subjected to MTS assay. Data are expressed as mean±SD of three independent experiments. B. Mutational status and ganetespib IC50 of cell lines.

23418523
In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: OSA cells
  • Concentrations: 0.001-1μM
  • Incubation Time: 5 days
  • Method: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Female severe combined immune-deficient (SCID) mice
  • Dosages: 25 mg/kg/day for 3 days
  • Administration: Tail vein injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 40 mg/mL (109.76 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02192541 Terminated Drug: Ziv-Aflibercept|Drug: Ganetespib Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 2 2014 Phase 1
NCT02008877 Completed Drug: ganetespib|Drug: Sirolimus Malignant Peripheral Nerve Sheath Tumors (MPNST)|Sarcoma Sarcoma Alliance for Research through Collaboration|Synta Pharmaceuticals Corp.|United States Department of Defense December 2013 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does this inhibitor inhibit both isoforms of HSP90?

  • Answer:

    We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Related HSP (HSP90) Products

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID